SAN DIEGO—(BUSINESS WIRE)—Nov. 30, 2018—ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical companyfocused on the development and commercialization of innovative medicinesto address unmet medical needs in central nervous system (CNS)disorders, today announced the closing of its previously announcedunderwritten public offering of 18,602,941 shares of its common stock,including 2,426,470 shares of common stock sold pursuant to theunderwriters’ full exercise of their option to purchase additionalshares, at a public offering price of $17.00 per share. The grossproceeds from the offering to ACADIA, before deducting underwritingdiscounts and commissions and other estimated offering expenses payableby ACADIA, are approximately $316.2 million.
BofA Merrill Lynch, J.P. Morgan Securities LLC and Goldman Sachs & Co.LLC acted as the joint book-running managers for the offering. Cowen andCompany, LLC acted as lead manager and Cantor Fitzgerald & Co., JMPSecurities LLC and Needham & Company, LLC acted as co-managers for theoffering.
The shares of common stock described above were offered by ACADIApursuant to a shelf registration statement filed by ACADIA with theSecurities and Exchange Commission (SEC) that became automaticallyeffective upon filing. A final prospectus supplement and accompanyingprospectus related to the offering were filed with the SEC and areavailable on the SEC’s website located at http://www.sec.gov.Copies of the final prospectus supplement and the accompanyingprospectus related to this offering may be obtained from BofA MerrillLynch, NC1-004-03-43, 200 North College Street, 3rd Floor,Charlotte, NC 28255-0001, Attn: Prospectus Department, Email: dg.prospectus_requests@baml.com,or from J.P. Morgan Securities LLC, Attention: Broadridge FinancialSolutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at(866) 803-9204, or by email to: prospectus-eq_fi@jpmchase.com,or from Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200West Street, New York, NY 10282, or by telephone at (866) 471-2526, orby email to: prospectus-ny@nyemail.gs.com.
This press release shall not constitute an offer to sell or thesolicitation of an offer to buy these securities, nor shall there be anysale of these securities in any state or other jurisdiction in whichsuch offer, solicitation or sale would be unlawful prior to theregistration or qualification under the securities laws of any suchstate or other jurisdiction.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceuticalcompany focused on the development and commercialization of innovativemedicines to address unmet medical needs in central nervous systemdisorders. ACADIA has developed and is commercializing the first andonly medicine approved for the treatment of hallucinations and delusionsassociated with Parkinson’s disease psychosis. In addition, ACADIA hasongoing clinical development efforts in additional areas withsignificant unmet need, including dementia-related psychosis,schizophrenia inadequate response, schizophrenia-negative symptoms,major depressive disorder, and Rett syndrome.
Source: ACADIA Pharmaceuticals Inc.
Investor Contact:
ACADIA Pharmaceuticals Inc.
ElenaRidloff, CFA
(858) 558-2871
ir@acadia-pharm.com
Media Contact:
ACADIA Pharmaceuticals Inc.
MaurissaMessier
(858) 768-6068
media@acadia-pharm.com